On May 1, 2018, Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Kymriah® (tisagenlecleucel) suspension for intravenous infusion for its second indication - the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.
Kymriah is not indicated for the treatment of patients with primary central nervous system lymphoma.
Read the company press release.
Read FDA announcement.
Posted 5/1/2018
In recognition of Leukemia and Lymphoma Awareness Month, ACCC compiled a group of resources to help care teams navigate two of the most commonly diagnosed adult leukemias: acute myeloid leukemia and chronic lymphocytic leukemia.
